SOURCE: BIOLASE, Inc.

BIOLASE, Inc.

September 30, 2013 09:20 ET

BIOLASE Closes Previously Announced $5 Million Registered Direct Offering

IRVINE, CA--(Marketwired - Sep 30, 2013) - BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, and a pioneer in laser surgery in other medical specialties, has closed its previously announced agreement to sell 2,688,172 shares of common stock in a registered direct public offering to a single investor, Camber Capital Management, LLC ("Camber").

The offering price of $1.86 per share, a price equal to the closing price on September 23, 2013, resulted in gross proceeds of $5 million, before deducting placement agent commissions of $250,000 and estimated offering expenses of approximately $100,000.

Northland Securities, Inc. acted as exclusive placement agent in connection with the offering.

Federico Pignatelli, Chairman and CEO of BIOLASE, said, "We are very pleased to have completed this financing which, along with the cash we expect to generate from operations in our 2013 fourth quarter, will provide us the capital necessary to continue our short-term growth. Throughout the years, BIOLASE's fourth quarter has traditionally been its best quarter. We are also excited to add Camber Capital Management as a high quality, long-term fundamental investor."

The shares were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-190158) filed pursuant to the Securities Act of 1933, as amended, which was previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC"). A prospectus supplement relating to the offering has been filed with the SEC and can be obtained at the SEC's website at http://www.sec.gov, at request from Northland Securities, Inc. by e-mailing Andrew Pafko at apafko@northlandcapitalmarkets.com, or from BIOLASE, Inc., 4 Cromwell, Irvine, California 92618.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of BIOLASE in this offering. There shall not be any offer, solicitation of an offer to buy, or for the sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment and CAD/CAM intraoral scanners; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's proprietary laser products incorporate approximately 315 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 23,000 lasers. Other laser products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase® and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Instagram at www.instagram.com/biolaseinc and YouTube at www.youtube.com/biolasevideos.

BIOLASE® and WaterLase® are registered trademarks of BIOLASE, Inc.

Additional Information
Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, but not limited to, the amount BIOLASE expects to receive from the offering and the timing for the closing of the offering. Forward-looking statements can be identified by the use of words such as "may," "will," "plan," "should," "expect," "anticipate," "estimate," "continue," or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends and uncertainties, many of which BIOLASE cannot predict with accuracy and some of which BIOLASE might not even anticipate, and involve factors that may cause actual results to differ materially from those projected or suggested. These risks and uncertainties include, among others, the factors described under the Risk Factors section of BIOLASE's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. BIOLASE cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and BIOLASE undertakes no obligation to update or revise the statements.

Contact Information

  • For further information, please contact:
    Michael Porter
    Porter, LeVay & Rose, Inc.
    212-564-4700